Loading…

What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis

Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fl...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-06, Vol.11, p.963-963
Main Authors: Li, Yao, Huang, Xiaojie, Qin, Yuanyuan, Wu, Hao, Yan, Xiaofeng, Chen, Yaokai
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3
cites cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3
container_end_page 963
container_issue
container_start_page 963
container_title Frontiers in pharmacology
container_volume 11
creator Li, Yao
Huang, Xiaojie
Qin, Yuanyuan
Wu, Hao
Yan, Xiaofeng
Chen, Yaokai
description Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM). We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens. The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant. Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.
doi_str_mv 10.3389/fphar.2020.00963
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691</doaj_id><sourcerecordid>2427523912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</originalsourceid><addsrcrecordid>eNpVkstu2zAQRYWiQROk2XdVcNmNXD5kSty0MIykEZAHEKTNkqDIkc1UElWSduGv66-VspMg4YbE8N4zg8HNsk8EzxirxNd2XCs_o5jiGcaCs3fZCeGc5aIi9P2r93F2FsIjTocJwXjxITtmtCQFqcRJ9u9hrSKqA4prQNcuRLQYR-9Gb1UEVA9mo6N1A7qDle1hQK3ze-m9BxVTISLXosv6V74IwenJZNDS78botNNadegaBjusbLQBPawTYDLfgXZ9MpskfganEW5c6r5VtlNNB9_R-dYaGDSgC-96pNANxL_O_07EqPLFoLpdsOFjdtSqLsDZ032a_bw4v19e5le3P-rl4irXBacxr0RJhCBgcENFWWBVkooIKDXVmFcwJ0XLcEXaAkzTVtwApxVWAOWczjlhmp1m9YFrnHqUaT298jvplJX7gvMrqXy0ugMJCrBhtCVlCQXhjWoA43auoTIguCCJ9e3AGjdND0anLXrVvYG-_RnsWq7cVpasKBilCfDlCeDdnw2EKHsbNHSdGsBtgqQFTYMzQSYpPki1dyF4aF_aECynGMl9jOQUI7mPUbJ8fj3ei-E5NOw_ErTHcA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2427523912</pqid></control><display><type>article</type><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><source>PubMed Central</source><creator>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</creator><creatorcontrib>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</creatorcontrib><description>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM). We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens. The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant. Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2020.00963</identifier><identifier>PMID: 32714189</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>antifungal regimen ; cryptococcal meningitis ; HIV ; induction treatment ; network meta-analysis ; Pharmacology</subject><ispartof>Frontiers in pharmacology, 2020-06, Vol.11, p.963-963</ispartof><rights>Copyright © 2020 Li, Huang, Qin, Wu, Yan and Chen.</rights><rights>Copyright © 2020 Li, Huang, Qin, Wu, Yan and Chen 2020 Li, Huang, Qin, Wu, Yan and Chen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</citedby><cites>FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344322/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344322/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32714189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yao</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Qin, Yuanyuan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Yan, Xiaofeng</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM). We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens. The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant. Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</description><subject>antifungal regimen</subject><subject>cryptococcal meningitis</subject><subject>HIV</subject><subject>induction treatment</subject><subject>network meta-analysis</subject><subject>Pharmacology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkstu2zAQRYWiQROk2XdVcNmNXD5kSty0MIykEZAHEKTNkqDIkc1UElWSduGv66-VspMg4YbE8N4zg8HNsk8EzxirxNd2XCs_o5jiGcaCs3fZCeGc5aIi9P2r93F2FsIjTocJwXjxITtmtCQFqcRJ9u9hrSKqA4prQNcuRLQYR-9Gb1UEVA9mo6N1A7qDle1hQK3ze-m9BxVTISLXosv6V74IwenJZNDS78botNNadegaBjusbLQBPawTYDLfgXZ9MpskfganEW5c6r5VtlNNB9_R-dYaGDSgC-96pNANxL_O_07EqPLFoLpdsOFjdtSqLsDZ032a_bw4v19e5le3P-rl4irXBacxr0RJhCBgcENFWWBVkooIKDXVmFcwJ0XLcEXaAkzTVtwApxVWAOWczjlhmp1m9YFrnHqUaT298jvplJX7gvMrqXy0ugMJCrBhtCVlCQXhjWoA43auoTIguCCJ9e3AGjdND0anLXrVvYG-_RnsWq7cVpasKBilCfDlCeDdnw2EKHsbNHSdGsBtgqQFTYMzQSYpPki1dyF4aF_aECynGMl9jOQUI7mPUbJ8fj3ei-E5NOw_ErTHcA</recordid><startdate>20200630</startdate><enddate>20200630</enddate><creator>Li, Yao</creator><creator>Huang, Xiaojie</creator><creator>Qin, Yuanyuan</creator><creator>Wu, Hao</creator><creator>Yan, Xiaofeng</creator><creator>Chen, Yaokai</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200630</creationdate><title>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</title><author>Li, Yao ; Huang, Xiaojie ; Qin, Yuanyuan ; Wu, Hao ; Yan, Xiaofeng ; Chen, Yaokai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antifungal regimen</topic><topic>cryptococcal meningitis</topic><topic>HIV</topic><topic>induction treatment</topic><topic>network meta-analysis</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yao</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Qin, Yuanyuan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Yan, Xiaofeng</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yao</au><au>Huang, Xiaojie</au><au>Qin, Yuanyuan</au><au>Wu, Hao</au><au>Yan, Xiaofeng</au><au>Chen, Yaokai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2020-06-30</date><risdate>2020</risdate><volume>11</volume><spage>963</spage><epage>963</epage><pages>963-963</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Our object was to find the most appropriate, most effective, and most readily available of four induction regimens for HIV-associated cryptococcal meningitis (CM) (Regimen A: 1 week of AmB plus 5-FC followed by 1 week of fluconazole, Regimen B: 1 week of AmB plus fluconazole followed by 1 week of fluconazole, Regimen C: 2 weeks of AmB plus 5-FC, Regimen D: 2 weeks of AmB plus fluconazole), given the vast differences between resource-limited and resource-abundant settings regarding therapeutic drug accessibility, availability, and affordability for HIV-associated (CM). We conducted a network meta-analysis to compare the therapeutic efficacy and safety of four different induction treatment regimens. The 10-week mortality of Regimen A was significantly lower than that of Regimen B and D, and the 2-week mortality of Regimen A was significantly lower than that of Regimen B. Furthermore, there were no statistically significant differences in 10-week mortality, 2-week mortality, as well as in effective fungicidal activity (EFA) over the first 2 weeks among Regimens B, C, and D. The statistical differences in adverse events between Regimen B and Regimen D, and Regimen C and Regimen D were not calculated to be significant. Our results indicate that, 1 week of AmB plus 5-FC followed by 1 week of fluconazole is superior to the three other studied regimens, and that when 5-FC is not available, accessible, or affordable, 2 weeks of AmB plus fluconazole or 1 week of AmB plus fluconazole followed by 1 week of fluconazole is an appropriate substitution for 2 weeks of AmB plus 5-FC.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32714189</pmid><doi>10.3389/fphar.2020.00963</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2020-06, Vol.11, p.963-963
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_eae0d32f177e416babe00f5ce8de9691
source PubMed Central
subjects antifungal regimen
cryptococcal meningitis
HIV
induction treatment
network meta-analysis
Pharmacology
title What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A28%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20Is%20the%20Most%20Appropriate%20Induction%20Regimen%20for%20the%20Treatment%20of%20HIV-Associated%20Cryptococcal%20Meningitis%20When%20the%20Recommended%20Regimen%20Is%20Not%20Available?%20Evidence%20From%20a%20Network%20Meta-Analysis&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Li,%20Yao&rft.date=2020-06-30&rft.volume=11&rft.spage=963&rft.epage=963&rft.pages=963-963&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2020.00963&rft_dat=%3Cproquest_doaj_%3E2427523912%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-8971991ed0b29740a71819e7c2c068e514f3081f4edbf86de6280aee7525613c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2427523912&rft_id=info:pmid/32714189&rfr_iscdi=true